Background. Ten chronic heart failure patients were studied on three occasions in randomized double-blind fashion to compare the acute hemodynamic, neurohormonal, and renal sodium-handling responses to 1 mg captopril versus 25 mg captopril, both in the absence of loop diuretic therapy and during furosemide-stimulated natriuresis.
Background. Ten chronic heart failure patients were studied on three occasions in randomized double-blind fashion to compare the acute hemodynamic, neurohormonal, and renal sodium-handling responses to 1 mg captopril versus 25 mg captopril, both in the absence of loop diuretic therapy and during furosemide-stimulated natriuresis.
Methods and Results. Compared with placebo, 1 mg captopril caused nonsignificant decreases in mean arterial pressure and circulating angiotensin II level and had no effect on glomerular filtration rate as determined by 5`Cr-EDTA elimination. Captopril (25 mg) produced marked suppression of serum angiotensin II with or without oral furosemide (both p<O.002), a marked decrease in mean arterial pressure (p<O.OOOl) that was accentuated by furosemide (p<O.OOOOl), and a decrease in glomerular filtration rate (p=0.0007). No difference from placebo in renal sodium excretion was noted with either 1 or 25 mg captopril in the absence of furosemide. In contrast, while 25 mg captopril caused slight attenuation of the natriuretic response to furosemide, 1 mg captopril significantly enhanced furosemideinduced natriuresis (p<0.05). No correlation was found in our patients between the natriuretic effect of furosemide and either absolute mean arterial pressure or change in mean arterial pressure during the furosemide phase of each study session. This suggests that blood pressure is not the important factor mediating the divergent renal responses to furosemide of the two captopril dosage regimens.
Conclusions. We propose that in the face of furosemide-induced postglomerular vasodilatation in chronic heart failure, captopril at a starting dose of 1 mg (but not 25 mg) preserves enough circulating angiotensin II to maintain efferent arteriolar tone and thus glomerular filtration, while offsetting the antinatriuretic renal tubular effects of angiotensin II. (Circulation 1992; 86:439-445) KEY WoRDs * captopril * furosemide * natriuresis * chronic heart failure F urosemide is used on a widespread basis in chronic heart failure (CHF) for its potent natriuretic actions. However, furosemide increases circulating levels of the already activated renin-angiotensin-aldosterone system (RAAS) via its direct reninreleasing action'2 and via its negative effects on extracellular fluid balance. 3 This RAAS activation may attenuate to some degree the efficacy of the loop diuretic in excreting salt and water. 3 Angiotensin converting enzyme Hawksley readings were used in the analysis of blood pressure for those two patients. Mean arterial pressure (MAP) was calculated as diastolic blood pressure plus one third of the pulse pressure. MAP for each 2-hour time interval was calculated as the mean value of all MAP readings during each individual 2-hour time period. Change in MAP (AMAP) was then calculated by subtracting the baseline (9:00 AM) MAP from the mean MAP for each 2-hour time interval. Baseline MAP was similar on all three study days. Effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) were estimated by established single-isotope injection techniques using 25I-iodohippurate and 5`Cr-EDTA, respectively.10"'1 Injections were given at 11:30 AM. ERPF was determined over the 44 minutes after injection, i.e., during the nondiuretic-treated phase of study, whereas GFR was determined over a 5½/2-hour period, incorporating the furosemide phase of study. Filtration fraction (FF) was calculated as GFR (ml/min)/ERPF (ml/min), and renal vascular resistance (RVR) was calculated as MAP (mm Hg)/[ERPF (1/min) x (1 -hematocrit)]. Blood and Urine Sample Collection and Analysis At 9:00 AM, after patients had lain supine for 30 minutes, baseline blood samples were drawn through the in-dwelling intravenous cannula for measurement of serum angiotensin II and plasma aldosterone. Further samples for the same measurements were drawn at 12:00 noon and 4:00 PM, coinciding with both the midpoint of urine collection periods and approximately with the peak ACE inhibitory activity of the appropriate oral doses of captopril, i.e., 1 hour after dose. Venous blood for plasma aldosterone was collected into chilled lithium heparin tubes, and samples for serum angiotensin II were collected into chilled plain glass tubes containing 0.5 ml of a solution comprising 0.05 M o-phenanthroline, 0.2 g/l neomycin, 0.125 M EDTAdisodium salt, and 2% ethanol. Samples were centrifuged immediately at 3,000g for 15 minutes at 4°C and separated. Aldosterone samples were frozen at -20°C and angiotensin II samples at -70°C until analysis. Angiotensin II was measured by radioimmunoassay (RIA) after extraction from serum samples using the method of Morton and Webb.12 This method, using Sep-Pak C-18 cartridges (Waters Associates, Mass.), removes a higher proportion of residual nonspecific interference than other resins, including that caused by the high level of circulating angiotensin I occurring after ACE inhibition. Aldosterone was also measured by RIA using a commercially available kit (Serono Diagnostics Ltd., UK).
At the end of each 2-hour collection period, the volume of urine voided was recorded, and a 10-ml aliquot taken for determination of urinary sodium concentration. Urine aliquots were stored at -20°C until analysis. Urinary sodium concentration was measured by flame photometry (943 flame photometer, Instrumentation Laboratory, Ltd., UK). Sodium excretion rate (UNaV) over each 2-hour time interval was calculated in gmol/min as urine flow rate (ml/min) x urine sodium concentration (mmol/l).
Statistical Analysis
Differences between treatment schedules were tested for significance using ANOVA Plasma Aldosterone There was a trend toward lowering of plasma aldosterone by 25 mg captopril with or without furosemide, but the change did not achieve statistical significance ( Figure 2 ). Captopril (1 mg) alone or in combination with furosemide yielded plasma aldosterone levels almost identical to those recorded on placebo treatment.
Mean Arterial Pressure
Captopril (1 mg) caused an insignificant fall in MAP either alone or in the presence of furosemide ( Figure 3 and Table 2 ). In contrast, a marked decrement in MAP was observed with 25 (Figure 4 ).
UNaV
Pretreatment UNaV was determined from a 24-hour urine specimen collected on the day before each study session. Compared with this baseline reading, sodium excretion was not changed acutely by placebo or by either dose of captopril in the absence of furosemide. The data shown in Figure 5 for captopril or placebo alone represent sodium excretion during the 11:00 AM-to-1:00 PM clearance interval.
Similar absolute values for the three treatments were recorded during the 9:00-11:00 AM and 1:00-3:00 PM clearance periods (data not shown A second possible pharmacokinetic mechanism to consider is that high-dose but not low-dose captopril may interfere with the gastrointestinal absorption of furosemide. This was suggested in one animal study in salt-depleted rats by the observation that intravenous captopril caused less inhibition of furosemide-induced natriuresis than oral captopril.26 However, no similar study has been performed in humans, and this latter mechanism does not explain why, in the animal study, intravenous captopril should have had any effect at all on furosemide-induced natriuresis.
In addition to the circulating RAAS, there are several other neurohumoral systems, including prostaglandin and kinin systems and the recently recognized intrarenal tissue RAAS, that influence renal homeostasis and are affected by ACE inhibition.5 These systems are also influenced by the loop diuretic furosemide, at least in the case of prostaglandins' and kinins.24 It is possible that high-dose captopril exerts an effect on one or more of these hormonal cascades that attenuates furosemideinduced natriuresis. Captopril (1 mg) may lack such an effect either because of lower dose per se or, in the case of an effect on the tissue RAAS, because of lack of intrarenal tissue penetration. In this context, both the intrarenal RAAS27 and the loop diuretic furosemide28,29 are thought to exert significant effects in redistributing intrarenal blood flow; in the case of furosemide, this effect may be integrally linked to its diuretic action. If this blood flow redistribution by furosemide were mediated by the intrarenal RAAS, one might anticipate interference with this effect and thus with natriuresis by high-but not low-dose captopril.
In our study, 1 These findings collectively support our own observations by suggesting that the RAAS preserves GFR in diuretic-treated CHF patients by maintaining efferent arteriolar tone and independent of its effects in sustaining systemic arterial pressure. Interestingly, high-dose diuretic therapy has been identified as one of the few important factors likely to lead to functional renal insufficiency after acute ACE inhibition.34 This has been attributed to the marked hypotensive effects of initial ACE inhibition in the setting of diuretic-induced extracellular fluid volume contraction and RAAS activation. However, the findings of our own study would question this explanation, suggesting that it is the unopposed postglomerular vasodilator effect of high-dose diuretic therapy that accounts for the observed fall in creatinine clearance after ACE inhibition. By reducing diuretic dose before ACE inhibition, one certainly restores ECF volume and limits hypotension, but the crucial factor may be that one is also decreasing the vasodilator influence exerted on the efferent arteriole.
Several studies that have shown initial falls in furosemide-induced natriuresis and GFR after ACE inhibition have demonstrated recovery in these parameters after weeks or months. 8'15-17 One potential criticism of our study is that the oral drugs administered were all given immediately before the clearance period under study. Furosemide and captopril are detectable in the blood of healthy volunteers at 10 and 15 minutes, respectively, after oral administration, with maximum plasma concentrations reduction in salt and water excretion. Imbs et a132
achieved after approximately 60 and 60-90 minutes, respectively.5,26 Absorption and, thus, time to maximum concentration may be prolonged in CHF. Therefore, it is clear that for part of the 2-hour study interval, the parameters under evaluation will be uninfluenced by the treatments administered. However, this would act as a negative bias on our results, so that the actual differences in effects of different treatment regimens may be even more marked than these observed.
In summary, we have demonstrated in a group of patients with moderately severe CHF that 25 mg captopril produced substantial initial falls in MAP, circulating angiotensin II, and GFR, associated with a slight blunting of furosemide-induced natriuresis. In contrast, 1 mg captopril markedly augmented the natriuretic effect of furosemide in the same patients, possibly by preserving enough circulating angiotensin II to maintain efferent arteriolar tone and thus GFR, while partially offsetting the tubular and glomerular antinatriuretic effects of the RAAS.
